Efficacy and safety of lebrikizumab in adult patients with mild-to-moderate asthma not receiving inhaled corticosteroids

Korenblat, Philip; Kerwin, E.M.; Лещенко, И. В.; Yen, Karl; Holweg, Cécile; Anzures-Cabrera, Judith; Martín, Carmen; Putnam, Wendy S.; Governale, Laura; Olsson, Julie; Matthews, John G.

doi:10.1016/j.rmed.2017.12.006

Cited by 53 publications

(33 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“… 13 Further studies assessed the safety and efficacy of AZD5069, another CXCR2 antagonist, as add-on therapy in patients with severe-uncontrolled asthma. 86 Treatment with this CXCR2-selective antagonist did not reduce the frequency of severe exacerbations, thus raising major doubts about the role of CXCR2-mediated neutrophil recruitment in severe refractory asthma exacerbations and potential clinical benefits.…”

Section: Ongoing Research: Failures Promises and Unmet Needsmentioning

confidence: 98%

Severe refractory asthma: current treatment options and ongoing research

Menzella¹,

Bertolini

Biava

et al. 2018

DIC

View full text Add to dashboard Cite

Patients with severe asthma have a greater risk of asthma-related symptoms, morbidities, and exacerbations. Moreover, healthcare costs of patients with severe refractory asthma are at least 80% higher than those with stable asthma, mainly because of a higher use of healthcare resources and chronic side effects of oral corticosteroids (OCS). The advent of new promising biologicals provides a unique therapeutic option that could achieve asthma control without OCS. However, the increasing number of available molecules poses a new challenge: the identification and selection of the most appropriate treatment. Thanks to a better understanding of the basic mechanisms of the disease and the use of predictive biomarkers, especially regarding the Th2-high endotype, it is now easier than before to tailor therapy and guide clinicians toward the most suitable therapeutic choice, thus reducing the number of uncontrolled patients and therapeutic failures. In this review, we will discuss the different biological options available for the treatment of severe refractory asthma, their mechanism of action, and the overlapping aspects of their usage in clinical practice. The availability of new molecules, specific for different molecular targets, is a key topic, especially when considering that the same targets are sometimes part of the same phenotype. The aim of this review is to help clarify these doubts, which may facilitate the clinical decision-making process and the achievement of the best possible outcomes.

show abstract

Section: Ongoing Research: Failures Promises and Unmet Needsmentioning

confidence: 98%

Severe refractory asthma: current treatment options and ongoing research

Menzella¹,

Bertolini

Biava

et al. 2018

DIC

View full text Add to dashboard Cite

show abstract

“…Therefore, this genetic variant could be considered a biomarker for patients with a high likelihood of responding to this treatment. Contemporaneous with this trial, a successful phase II trial with lebrikizumab (an anti-IL-13 mAb) for treatment of asthma indicated the secreted protein periostin as a biomarker for patient selection (46); however, lebrikizumab did not show efficacy in a multicenter phase III trial (47).…”

Section: Targeting the Mediators Of The Allergic Responsementioning

confidence: 95%

The use of biologics for immune modulation in allergic disease

Veen¹,

Akdiş²

2019

Journal of Clinical Investigation

View full text Add to dashboard Cite

“…Korenblat et al reported anaphylaxis in one patient (1 %) treated with lebrikizumab, and this reaction was attributed to a known peanut allergy [11]. In another study, lebrikizumab was well tolerated, and death and anaphylactic reactions were not reported [12].…”

Section: Lebrikizumabmentioning

confidence: 98%

Hypersensitivity reactions to biologics (part I): allergy as an important differential diagnosis in complex immune-derived adverse events*

Gülşen¹,

Wedi²,

Jappe³

2020

Allergo J

View full text Add to dashboard Cite

Purpose: Biotechnological substances (BSs) are strongly relied upon to prevent rejection of transplanted organs, and to treat oncological, allergological, and other inflammatory diseases. Allergic reactions to partly foreign biologics can occur due to their potential immunogenicity. The severity of an immune response to a biological drug may range from no clinical significance to a severe, life-threatening anaphylactic reaction. Methods: Detailed searches were performed on Pubmed, Web of Science, and Google Scholar to include all available publications. In addition, the Food and Drug Administration, the European Medicines Agency, and British Columbia Cancer Agency Drug Manual databases were screened for hypersensitivity reaction (HSR), infusion reaction, injection site reaction, urticaria, and anaphylaxis for individual BSs. Results: Treatment with BSs can cause various types of HSR. These are mentioned in the literature with definitions such as allergic reactions, anaphylactoid reactions, anaphylaxis, HSR, infusion reactions, injection site reactions, cytokine release syndrome, and urticaria. Due to the overlap in signs and symptoms in the reported descriptions, it is not always possible to differentiate these reactions properly according to their pathomechanism. Similarly, many data reported as anaphylaxis actually describe severe anaphylactic reactions (grades III or IV). Conclusion: There is an urgent need for a simpler symptom-or system-based classification and scoring system to create an awareness for HSRs to BSs. A better understanding of the pathophysiology of HSRs and increased clinical experience in the treatment of side effects will provide timely control of unexpected reactions. As a result, immunotherapy with BSs will become safer in the future. Cite this as Gülsen A, Wedi B, Jappe U. Hypersensitivity reactions to biologics (part I): allergy as an important differential diagnosis in complex immune-derived adverse events.

show abstract

Efficacy and safety of lebrikizumab in adult patients with mild-to-moderate asthma not receiving inhaled corticosteroids

Abstract: This trial was registered under NCT02104674 at http://www.clinicaltrials.gov.

Cited by 53 publications

References 16 publications

Severe refractory asthma: current treatment options and ongoing research

Severe refractory asthma: current treatment options and ongoing research

The use of biologics for immune modulation in allergic disease

Hypersensitivity reactions to biologics (part I): allergy as an important differential diagnosis in complex immune-derived adverse events*

Contact Info

Product

Resources

About